ReviewCurrent hypertension reports2003
Regression of left ventricular hypertrophy is a key goal of hypertension management.
Review in Current hypertension reports, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 25 citations in OpenAlex.
- Influence of renovascular hypertension on the distribution of vasoactive intestinal peptide in the stomach and heart of rats.Experimental biology and medicine (Maywood, N.J.) · 2015Article
- BP control and left ventricular hypertrophy regression in children with CKD.Journal of the American Society of Nephrology : JASN · 2014Article
- Transcriptional network analysis for the regulation of left ventricular hypertrophy and microvascular remodeling.Journal of cardiovascular translational research · 2013Article
- Improvement of left ventricular mass with antihypertensive therapy in children with hypertension.Pediatric nephrology (Berlin, Germany) · 2010Article
- Effect of yiqi huoxue recipe on cardiac function and ultrastructure in regression of pressure overload-induced myocardial hypertrophy in rats.Chinese journal of integrative medicine · 2007Article
- Guiding antihypertensive treatment decisions using ambulatory blood pressure monitoring.Current hypertension reports · 2006Review
- Distinct QTLs are linked to cardiac left ventricular mass in a sex-specific manner in a normotensive inbred rat inter-cross.Mammalian genome : official journal of the International Mammalian Genome Society · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Left ventricular hypertrophy (LVH) in patients with hypertension is associated with an increased risk for many cardiovascular events and predicts a higher mortality rate. The pathogenesis of LVH is complicated. In addition to the hemodynamic burden (pressure or volume overload) and demographic factors, several trophic humoral factors, such as angiotensin II, aldosterone, endothelin, leptin, and catecholamines, may also contribute to the development and progression of LVH. Effective antihypertensive therapy can reverse LVH as well as prevent its development. Regression of LVH decreases subsequent cardiovascular morbidity and mortality. The commonly used drugs have various effects on LVH. Angiotensin receptor blockers and angiotensin-converting enzyme inhibitors seem most effective. Several new agents, including direct antifibrotic drugs, aldosterone blockade, vasopeptidase inhibitors, and endothelin receptor antagonists that more specifically target the underlying pathogenesis of LVH may provide us with innovative approaches to treat LVH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.